Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Bevacizumab in neovascular AMD (MANTA)
NCT00710229Phase 3Unknown
- Sponsor
- Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
- Start
- Jul 2008
- Primary completion
- Dec 2011
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab and bevacizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery. Primary endpoint: Best Corrected Visual Acuity at 12 months. Status: unknown.
02
Drugs
ranibizumabbevacizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00710229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00710229.